

Indoco Q2FY19 Revenues at Rs. 236 Crores

Mumbai, November 13, 2018: Indoco Remedies posted revenues of ₹ 235.9 crores during the second quarter of FY 2018-19, as against ₹ 280.0 crores, for the same quarter last year. Sequentially, the revenues for the quarter were higher by 11.0 % (₹ 235.9 crores, as against ₹ 212.5 crores) The Company posted a loss of ₹ 7.8 crores, as against profit of ₹ 19.8 crores, for the same quarter last year and a loss of ₹ 12.0 crores in the immediate preceding quarter.

Commenting on the 2nd quarter results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “In Domestic Formulations Business, Indoco recorded 7.2 % growth in the first half, which is closer to the Industry growth. On the International business front, the recent MHRA inspections at our facilities have gone well and we will soon see revival in Exports”.

For the quarter ended Sept’18, the financials are as under:

(₹ in Crores)

Particulars	July’18- Sept’18	April’18- June’18	July’17- Sept’17
Net Revenues	235.9	212.5	280.0
EBIDTA	11.8	11.6	40.9
Operating Profit	1.9	0.88	28.5
Profit / (Loss) After Tax	(7.8)	(12.0)	19.8
EPS (Face value ₹ 2/-) (Not annualized)	(0.85)	(1.30)	2.14

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 161 million Company, employs over 5500 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The

facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Tuspel Plus, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com / corpcom@indoco.com